EUVIMEDEUVIMED entdecken
Crossref

Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies

Wenyue Cao, Fankai Meng, Sizhou Feng, Mingfeng Zhao, Jianxin Song, Yuqian Sun, Weijie Cao, Weiwei Tian, Yongxian Hu, Fangyi Fan, Xiaowen Tang, Wenbin Qian und 2 weitere

Journal of Evidence-Based Medicine · 2026-03 · 19 (1)

DOI: 10.1111/jebm.70107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Evidence-Based Medicine, online erschienen am 14.01.2026. Verfasst von Wenyue Cao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Cytomegalovirus Infections, Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Hubei Province, National High Technology Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) is an increasingly recognized complication of chimeric antigen receptor T‐cell (CAR‐T) and bispecific antibody (BsAb) therapies for hematologic malignancies, driven by therapy‐related immunosuppression and cumulative exposure to lymphodepleting or steroid regimens. Given China's high adult CMV IgG seroprevalence (>90%), baseline risk, interpretation of low‐level DNAemia, and operational thresholds differ from low‐seroprevalence settings, requiring context‐specific guidance. This China‐adapted, evidence‐graded consensus was developed by a multidisciplinary panel from major centers using a modified Delphi process and Oxford Centre for Evidence‐Based Medicine levels to translate international guidance into a high‐seroprevalence setting. Recommendations prioritize early risk stratification and pragmatic surveillance. We advise routine CMV monitoring by real‐time quantitative PCR during the first 30 days after therapy, with risk‐adapted extension thereafter. Interpretation and treatment triggers are anchored to WHO‐traceable IU/mL and specified by specimen matrix to support comparability across assays. Consideration of prophylaxis is proposed for well‐defined high‐risk subgroups, acknowledging the need for prospective validation. Syndrome‐based diagnostic and treatment algorithms are provided for tissue‐invasive disease, including CMV pneumonia and encephalitis, with guidance on antiviral induction, step‐down, and monitoring for virologic response and drug toxicity. This consensus explicitly adapts international recommendations to China's epidemiology, assay practice, and drug accessibility. By standardizing prevention, surveillance, and management in CAR T‐cell and BsAb recipients, this consensus aims to lower non‐relapse mortality and improve long‐term outcomes. Priority research needs include harmonized viral‐load thresholds, validation of risk‐adapted prophylaxis strategies, and studies that clarify the significance of low‐level DNAemia in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCytomegalovirus InfectionsImmunotherapy, AdoptiveHumansAntiviral Agents

Stichwörter der Autor:innen

CAR‐T therapyDelphi consensusbispecific antibodiescytomegalovirusguideline adaptationinfection management

Substanzen

Antibodies, BispecificAntiviral Agents

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • State Key Laboratory of Experimental Hematology and National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical C…
  • Department of Hematology, Tianjin First Central Hospital, The First Affiliated Central Hospital of Nankai University, The First Central Clinical College of Tianjin Medical University, Tianjin, China.
  • Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • National Clinical Research Center for Hematologic Disease, Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chi…

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development Program of Hubei Province
  • National High Technology Research and Development Program of China

Zitieren

APA

Cao, W., Meng, F., Feng, S., Zhao, M., Song, J., Sun, Y., Cao, W., Tian, W., Hu, Y., Fan, F., Tang, X., Qian, W., Zhang, Y., & Wei, J. (2026). Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies. Journal of Evidence-Based Medicine, 19(1). https://doi.org/10.1111/jebm.70107

Vancouver

Cao W, Meng F, Feng S, Zhao M, Song J, Sun Y, et al. Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies. Journal of Evidence-Based Medicine. 2026;19(1). doi:10.1111/jebm.70107

BibTeX
@article{Cao2026,
  author = {Cao, Wenyue and Meng, Fankai and Feng, Sizhou and Zhao, Mingfeng and Song, Jianxin and Sun, Yuqian and Cao, Weijie and Tian, Weiwei and Hu, Yongxian and Fan, Fangyi and Tang, Xiaowen and Qian, Wenbin and Zhang, Yicheng and Wei, Jia},
  title = {Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies},
  journal = {Journal of Evidence-Based Medicine},
  year = {2026},
  volume = {19},
  number = {1},
  doi = {10.1111/jebm.70107}
}
Kostenlos starten →